Federal Register of Legislation - Australian Government

Primary content

National Health (Continued Dispensing) Determination 2022

Authoritative Version
  • - F2022C00991
  • In force - Superseded Version
  • View Series
PB 59 of 2022 Determinations/Health as amended, taking into account amendments up to National Health (Continued Dispensing) Amendment Determination 2022 (No. 1)
This instrument expands the list of eligible medicines that can be obtained under Continued Dispensing arrangements and repeals the National Health (Continued Dispensing) Determination 2012 and the National Health (Continued Dispensing – Emergency Measures) Determination 2020.
Administered by: Health and Aged Care
Registered 08 Oct 2022
Start Date 01 Oct 2022
End Date 31 Jul 2023

Commonwealth Coat of Arms of Australia

National Health (Continued Dispensing) Determination 2022

PB 59 of 2022

made under subsection 89A(3) of the

National Health Act 1953

Compilation No. 1

Compilation date:                              1 October 2022

Includes amendments up to:            F2022L01306

Registered:                                         8 October 2022

About this compilation

This compilation

This is a compilation of the National Health (Continued Dispensing) Determination 2022 that shows the text of the law as amended and in force on 1 October 2022 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Self‑repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

  

  

  


Contents

Part 1—Preliminary                                                                                                                                        1

1.01....... Name............................................................................................................................. 1

1.02....... Commencement............................................................................................................. 1

1.03....... Authority....................................................................................................................... 1

1.04....... Schedule 2..................................................................................................................... 1

1.05....... Definitions..................................................................................................................... 1

1.06....... Purpose......................................................................................................................... 2

Part 2—Pharmaceutical benefits that may be supplied without a prescription         3

2.01....... Pharmaceutical benefits covered by this instrument....................................................... 3

Part 3—Specified conditions for supplying pharmaceutical benefits without a prescription     4

3.01....... General.......................................................................................................................... 4

3.02....... Condition—unable to obtain prescription...................................................................... 4

3.03....... Condition—previous supply of pharmaceutical benefit................................................. 4

3.04....... Condition—stability of therapy..................................................................................... 4

3.05....... Condition—prior clinical review by PBS prescriber..................................................... 4

3.06....... Condition—prescription for last supply of pharmaceutical benefit................................ 5

3.07....... Condition—no continued dispensing in previous 12 months........................................ 5

3.08....... Condition—declaration for supply of pharmaceutical benefit........................................ 5

3.09....... Condition—maximum quantity of supply..................................................................... 5

3.10....... Condition—preparing and recording information.......................................................... 5

Part 4—Application, savings and transitional provisions                                                        7

4.01....... Application of this instrument....................................................................................... 7

Schedule 1—Pharmaceutical benefits that may be supplied without a prescription  8

1............ Pharmaceutical benefits that may be supplied without a prescription by an approved pharmacist            8

Schedule 2—Repeals                                                                                                                                     14

National Health (Continued Dispensing) Determination 2012                                                 14

National Health (Continued Dispensing – Emergency Measures) Determination 2020       14

Endnotes                                                                                                                                                               15

Endnote 1—About the endnotes                                                                                                      15

Endnote 2—Abbreviation key                                                                                                          16

Endnote 3—Legislation history                                                                                                       17

Endnote 4—Amendment history                                                                                                     18

 


Part 1Preliminary

  

1.01  Name

             (1)  This instrument is the National Health (Continued Dispensing) Determination 2022.

             (2)  This instrument may also be cited as PB 59 of 2022.

1.02  Commencement

             (1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 July 2022.

1 July 2022

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

1.03  Authority

                   This instrument is made under subsection 89A(3) of the National Health Act 1953.

1.04  Schedule 2

                   Each instrument that is specified in Schedule 2 to this instrument is amended or repealed as set out in the applicable items in that Schedule, and any other item in that Schedule has effect according to its terms.

1.05  Definitions

             (1)  In this instrument:

Act means the National Health Act 1953.

electronic prescription has the meaning given by subsection 5(1) of the Regulations.

patient: see subsection 3.01(1).

Regulations means the National Health (Pharmaceutical Benefits) Regulations 2017.

requested supply: see subsection 3.01(1).

             (2)  An expression that is used in this instrument and in Part VII of the Act has the same meaning in this instrument as it has in that Part.

Examples:

(a)    approved pharmacist;

(b)    listed brand;

(c)    PBS prescriber;

(d)    pharmaceutical benefit;

(e)    pharmaceutical item;

(f)    Schedule equivalent.

1.06  Purpose

                   The purpose of this instrument is to determine:

                     (a)  the pharmaceutical benefits that may be supplied by an approved pharmacist without a prescription; and

                     (b)  the conditions that must be satisfied when making a supply of those pharmaceutical benefits.

Part 2Pharmaceutical benefits that may be supplied without a prescription

  

2.01  Pharmaceutical benefits covered by this instrument

                   For the purposes of paragraph 89A(3)(a) of the Act, the pharmaceutical benefits covered by an item in the table in Schedule 1 (being the listed drugs specified in the item) are determined to be pharmaceutical benefits that may be supplied by an approved pharmacist without a prescription.

Part 3Specified conditions for supplying pharmaceutical benefits without a prescription

  

3.01  General

             (1)  For the purposes of paragraph 89A(3)(b) of the Act, the conditions specified in this Part are determined to be the conditions that must be satisfied when making a supply (the requested supply) of a pharmaceutical benefit to a person (the patient) requesting the supply without a prescription in accordance with subsection 89A(1) of the Act.

             (2)  In this Part:

                     (a)  a reference to the PBS prescriber is a reference to the PBS prescriber who most recently prescribed the supply of the pharmaceutical benefit to the patient; and

                     (b)  a reference to “the pharmaceutical benefit” in sections 3.03, 3.05, 3.06 and 3.07 includes a reference to a pharmaceutical benefit that is a Schedule equivalent.

3.02  Condition—unable to obtain prescription

                   The approved pharmacist must be satisfied of either or both of the following:

                     (a)  the PBS prescriber is unable to be contacted;

                     (b)  the PBS prescriber is unable to provide an electronic prescription.

3.03  Condition—previous supply of pharmaceutical benefit

                   The approved pharmacist must be satisfied that:

                     (a)  the patient has previously been supplied the pharmaceutical benefit on the basis of a prescription from a PBS prescriber; and

                     (b)  the PBS prescriber prescribed the supply of the pharmaceutical benefit for the patient in at least one of the circumstances determined for that pharmaceutical benefit under paragraph 85(7)(b) of the Act.

Note:          The circumstances determined under paragraph 85(7)(b) of the Act relate to pharmaceutical benefits that are relevant pharmaceutical benefits under section 88A of the Act.

3.04  Condition—stability of therapy

                   The approved pharmacist must be satisfied that the patient’s therapy is stable.

3.05  Condition—prior clinical review by PBS prescriber

                   The approved pharmacist must be satisfied that:

                     (a)  the patient has been taking the pharmaceutical benefit regularly for an uninterrupted period; and

                     (b)  since the start of that period, the PBS prescriber has assessed the patient’s condition and decided that there is a need for ongoing treatment with the pharmaceutical benefit.

Note:          See paragraph 3.01(2)(a) for references to the PBS prescriber.

3.06  Condition—prescription for last supply of pharmaceutical benefit

                   The approved pharmacist must be satisfied that the patient had a valid prescription under Part VII of the Act for the last supply of the pharmaceutical benefit to the patient before the requested supply.

3.07  Condition—no continued dispensing in previous 12 months

                   The approved pharmacist must be satisfied that the patient was not supplied with the pharmaceutical benefit under subsection 89A(1) of the Act in the 12 months before the requested supply.

3.08  Condition—declaration for supply of pharmaceutical benefit

                   The approved pharmacist must ensure that the patient, or an agent of the patient (other than the approved pharmacist), signs a declaration acknowledging that the patient is being supplied with the pharmaceutical benefit without the presentation of a valid prescription under Part VII of the Act.

3.09  Condition—maximum quantity of supply

                   The approved pharmacist must supply a maximum quantity or number of units of the pharmaceutical item in the pharmaceutical benefit determined under paragraph 85A(2)(a) of the Act.

3.10  Condition—preparing and recording information

             (1)  The approved pharmacist must, when the pharmaceutical benefit is supplied:

                     (a)  record the information that the pharmacist used to support the pharmacist’s decision to supply the pharmaceutical benefit; and

                     (b)  prepare information about the supply to the patient that the pharmacist will send to the PBS prescriber.

             (2)  The information that must be recorded and prepared under subsection (1) must include the following:

                     (a)  a statement that the pharmaceutical benefit supplied is a pharmaceutical benefit covered by Schedule 1;

                     (b)  a statement that the conditions mentioned in sections 3.02 to 3.05 are satisfied;

                     (c)  a statement that the approved pharmacist is satisfied that the pharmaceutical benefit needs to be supplied to the patient to facilitate continuity of treatment.

Part 4Application, savings and transitional provisions

  

4.01  Application of this instrument

                   Despite the repeal of the National Health (Continued Dispensing – Emergency Measures) Determination 2020, that instrument (the emergency instrument) continues to have effect, on and after 1 July 2022, for the purposes of the National Health (Supply of Pharmaceutical Benefits—Under Co‑payment Data and Claims for Payment) Rules 2022 in relation to a supply of a pharmaceutical benefit made in accordance with the emergency instrument on or before 30 June 2022 as if the repeal had not happened.

Schedule 1Pharmaceutical benefits that may be supplied without a prescription

Note:       See section 3.01.

  

  

1  Pharmaceutical benefits that may be supplied without a prescription by an approved pharmacist

 

Item

Listed drug

1

Abacavir

2

Abacavir with lamivudine

3

Abacavir with lamivudine and zidovudine

4

Acarbose

5

Adefovir

6

Alogliptin

7

Alogliptin with metformin

8

Amlodipine

9

Amlodipine with atorvastatin

10

Amlodipine with valsartan

11

Amlodipine with valsartan and hydrochlorothiazide

12

Atazanavir

13

Atazanavir with cobicistat

14

Atenolol

15

Atorvastatin

16

Beclometasone

17

Beclometasone with formoterol

18

Bictegravir with emtricitabine with tenofovir alafenamide

19

Bisoprolol

20

Budesonide

21

Budesonide with formoterol

22

Candesartan

23

Candesartan with hydrochlorothiazide

24

Captopril

25

Carvedilol

26

Chlortalidone

27

Ciclesonide

28

Cromoglycic acid

29

Dapagliflozin

30

Dapagliflozin with metformin

31

Darunavir

32

Darunavir with cobicistat

33

Darunavir with cobicistat, emtricitabine and tenofovir alafenamide

34

Diltiazem

35

Dolutegravir

36

Dolutegravir with abacavir and lamivudine

37

Dolutegravir with lamivudine

38

Dolutegravir with rilpivirine

39

Dulaglutide

40

Efavirenz

41

Empagliflozin

42

Empagliflozin with linagliptin

43

Empagliflozin with metformin

44

Emtricitabine with rilpivirine with tenofovir alafenamide

45

Emtricitabine with tenofovir alafenamide

46

Enalapril

47

Enalapril with hydrochlorothiazide

48

Enfuvirtide

49

Entecavir

50

Eplerenone

51

Eprosartan

52

Eprosartan with hydrochlorothiazide

53

Ertugliflozin

54

Ertugliflozin with metformin

55

Ertugliflozin with sitagliptin

56

Etravirine

57

Exenatide

58

Ezetimibe and rosuvastatin

59

Ezetimibe with atorvastatin

60

Ezetimibe with simvastatin

61

Felodipine

62

Fluticasone furoate

63

Fluticasone furoate with vilanterol

64

Fluticasone propionate

65

Fluticasone propionate with formoterol

66

Fluticasone propionate with salmeterol

67

Fluvastatin

68

Formoterol

69

Fosamprenavir

70

Fosinopril

71

Fosinopril with hydrochlorothiazide

72

Furosemide

73

Glibenclamide

74

Gliclazide

75

Glimepiride

76

Glipizide

77

Hydrochlorothiazide

78

Hydrochlorothiazide with amiloride

79

Indacaterol

80

Indacaterol with mometasone

81

Indapamide

82

Insulin aspart

83

Insulin aspart with insulin aspart protamine suspension

84

Insulin degludec with insulin aspart

85

Insulin detemir

86

Insulin glargine

87

Insulin glulisine

88

Insulin isophane

89

Insulin lispro

90

Insulin lispro with insulin lispro protamine suspension

91

Insulin neutral

92

Insulin neutral with insulin isophane

93

Irbesartan

94

Irbesartan with hydrochlorothiazide

95

Labetalol

96

Lamivudine

97

Lamivudine with zidovudine

98

Lercanidipine

99

Lercanidipine with enalapril

100

Levonorgestrel

101

Levonorgestrel with ethinylestradiol

102

Linagliptin

103

Linagliptin with metformin

104

Lisinopril

105

Lopinavir with ritonavir

106

Losartan

107

Maraviroc

108

Metformin

109

Metoprolol

110

Metoprolol succinate

111

Nebivolol

112

Nevirapine

113

Nifedipine

114

Norethisterone

115

Norethisterone with ethinylestradiol

116

Norethisterone with mestranol

117

Olmesartan

118

Olmesartan with amlodipine

119

Olmesartan with amlodipine and hydrochlorothiazide

120

Olmesartan with hydrochlorothiazide

121

Oxprenolol

122

Perindopril

123

Perindopril with amlodipine

124

Perindopril with indapamide

125

Pindolol

126

Pioglitazone

127

Pravastatin

128

Propranolol

129

Quinapril

130

Quinapril with hydrochlorothiazide

131

Raltegravir

132

Ramipril

133

Ramipril with felodipine

134

Rilpivirine

135

Ritonavir

136

Rosuvastatin

137

Sacubitril with valsartan

138

Salbutamol

139

Salmeterol

140

Saquinavir

141

Saxagliptin

142

Saxagliptin with dapagliflozin

143

Saxagliptin with metformin

144

Semaglutide

145

Simvastatin

146

Sitagliptin

147

Sitagliptin with metformin

148

Spironolactone

149

Telmisartan

150

Telmisartan with amlodipine

151

Telmisartan with hydrochlorothiazide

152

Tenofovir

153

Tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat

154

Tenofovir with emtricitabine

155

Tenofovir with emtricitabine and efavirenz

156

Terbutaline

157

Tipranavir

158

Trandolapril

159

Trandolapril with verapamil

160

Valsartan

161

Valsartan with hydrochlorothiazide

162

Verapamil

163

Vildagliptin

164

Vildagliptin with metformin

165

Zidovudine


Schedule 2Repeals

  

National Health (Continued Dispensing) Determination 2012

1  The whole of the instrument

Repeal the instrument.

National Health (Continued Dispensing – Emergency Measures) Determination 2020

2  The whole of the instrument

Repeal the instrument.


Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnote 2—Abbreviation key

ad = added or inserted

o = order(s)

am = amended

Ord = Ordinance

amdt = amendment

orig = original

c = clause(s)

par = paragraph(s)/subparagraph(s)

C[x] = Compilation No. x

/sub‑subparagraph(s)

Ch = Chapter(s)

pres = present

def = definition(s)

prev = previous

Dict = Dictionary

(prev…) = previously

disallowed = disallowed by Parliament

Pt = Part(s)

Div = Division(s)

r = regulation(s)/rule(s)

ed = editorial change

reloc = relocated

exp = expires/expired or ceases/ceased to have

renum = renumbered

effect

rep = repealed

F = Federal Register of Legislation

rs = repealed and substituted

gaz = gazette

s = section(s)/subsection(s)

LA = Legislation Act 2003

Sch = Schedule(s)

LIA = Legislative Instruments Act 2003

Sdiv = Subdivision(s)

(md) = misdescribed amendment can be given

SLI = Select Legislative Instrument

effect

SR = Statutory Rules

(md not incorp) = misdescribed amendment

Sub‑Ch = Sub‑Chapter(s)

cannot be given effect

SubPt = Subpart(s)

mod = modified/modification

underlining = whole or part not

No. = Number(s)

commenced or to be commenced

 

Endnote 3—Legislation history

 

Name

Registration

Commencement

Application, saving and transitional provisions

National Health (Continued Dispensing) Determination 2022 (PB 59 of 2022)

30 June 2022 (F2022L00884)

1 July 2022 (s 2(1) item 1)

 

National Health (Continued Dispensing) Amendment Determination 2022 (No. 1) (PB 88 of 2022)

30 Sept 2022 (F2022L01306)

1 Oct 2022 (s 2(1) item 1)

 

Endnote 4—Amendment history

 

Provision affected

How affected

Part 1

 

s 1.02........................................

rep LA s 48D

s 1.04........................................

rep LA s 48C

Schedule 1

 

s 1.............................................

am F2022L01306

Schedule 2

 

Schedule 2................................

rep LA s48C